Lawrence Berk

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Egfrviii-expressing Glioblastoma, Neuro-oncology, Act Iv +10

RTOG 0631 phase 2/3 study of image guided stereotactic radiosurgery for localized (1-3) spine metastases: Phase 2 results

Samuel Ryu, Stephanie L. Pugh, Peter C. Gerszten et al. · Practical Radiation Oncology · 2013 · 262 citations · Full text

Adaptive Radiotherapy, Neuro-oncology, Surgical Oncology +14

Single‐fraction radiotherapy versus multifraction radiotherapy for palliation of painful vertebral bone metastases—Equivalent efficacy, less toxicity, more convenient

David D. Howell, J. James, William F. Hartsell et al. · Cancer · 2012 · 149 citations · Full text

A randomized, double-blind, placebo-controlled trial of a β-hydroxyl β-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122)

Lawrence Berk, J. James, Anna L. Schwartz et al. · Supportive Care in Cancer · 2008 · 115 citations

Oncology, Cancer Cachexia, Rtog 0122 +10

Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial

Ethan Basch, Stephanie L. Pugh, Amylou C. Dueck et al. · International Journal of Radiation Oncology*Biology*Physics · 2017 · 115 citations · Full text

Adverse Events, Oncology, Adverse Event +10